Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection
Kailera Therapeutics Inc NASDAQ:KLRA
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Kailera Therapeutics completes enrollment in KaiNETIC Phase 3
Kailera Therapeutics announced completion of enrollment in KaiNETIC, its global Phase 3 clinical program of ribupatide injection, a GLP-1/GIP receptor dual agonist.